Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to ...

IRA’s $2,000 out-of-pocket cap helps few; most won’t hit the threshold Insurers raise deductibles, replace flat co-pays with ...

Two drugs – donanemab and lecanemab – have been rejected for NHS use because their benefits are "too small" to justify their ...

Lantern Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer Contacts Investor Relations [email protected] ...